Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated With Miransertib in Other Studies
Conditions
Interventions
Miransertib
Locations
11
United States
Children's Healthcare of Atlanta - Egleston Hospital ( Site 0107)
Atlanta, Georgia, United States
Boston Children's Hospital ( Site 0089)
Boston, Massachusetts, United States
Cincinnati Children's Hospital Medical Center-Hematology ( Site 0102)
Cincinnati, Ohio, United States
Texas Children's Hospital ( Site 0104)
Houston, Texas, United States
Seattle Children's Hospital ( Site 0103)
Seattle, Washington, United States
John Hunter Hospital ( Site 0203)
Newcastle, New South Wales, Australia
Start Date
November 2, 2021
Primary Completion Date
February 7, 2030
Completion Date
February 7, 2030
Last Updated
February 7, 2025
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions